1-2 of 2
Jing Gong, PhD
Close
Sort by
Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 643.
https://doi.org/10.1182/blood-2019-130362
Published: 2019
Journal Articles

Mutant Isocitrate Dehydrogenase (mIDH) Inhibitors, Enasidenib or Ivosidenib, in Combination with Azacitidine (AZA): Preliminary Results of a Phase 1b/2 Study in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Courtney D. DiNardo, MDMSc, Anthony S. Stein, MD, Amir T. Fathi, MD MD BS, Pau Montesinos, MD PhD, Olatoyosi Odenike, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Daniel O. Koralek, PhD, Jason Van Oostendorp, M.Sc., Jing Gong, PhD, Ira Gupta, MD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath
Journal: Blood
Blood (2017) 130 (Supplement 1): 639.
https://doi.org/10.1182/blood.V130.Suppl_1.639.639
Published: 2017